Factive

Gemifloxacin mesylate

On July 8, 2008, the Food and Drug Administration (FDA) announced it notified manufacturers of fluoroquinolone drugs that a warning on the product labeling concerning an increased risk of tendinitis and tendon rupture is necessary. Factive is one of these drugs.